These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 34174989)
1. Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond. Shadman M; Maloney DG Hematol Oncol Clin North Am; 2021 Aug; 35(4):847-862. PubMed ID: 34174989 [TBL] [Abstract][Full Text] [Related]
2. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia. Bair SM; Porter DL Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173 [TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia: Are We Any Closer to a Cure? Rhodes JM; Schuster SJ Cancer J; 2019; 25(6):436-441. PubMed ID: 31764125 [TBL] [Abstract][Full Text] [Related]
4. CAR T-cell therapy for CLL: a new addition to our treatment toolbox? Iovino L; Shadman M Clin Adv Hematol Oncol; 2023 Mar; 21(3):134-141. PubMed ID: 36867557 [TBL] [Abstract][Full Text] [Related]
5. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249 [TBL] [Abstract][Full Text] [Related]
6. Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade? Katz OB; Yehudai-Ofir D; Zuckerman T Acta Haematol; 2024; 147(1):99-112. PubMed ID: 37812926 [TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. Zou Y; Xu W; Li J J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878 [TBL] [Abstract][Full Text] [Related]
8. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672 [TBL] [Abstract][Full Text] [Related]
9. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313 [TBL] [Abstract][Full Text] [Related]
10. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419 [TBL] [Abstract][Full Text] [Related]
11. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. Smolewski P; Robak T Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270 [TBL] [Abstract][Full Text] [Related]
12. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M Front Immunol; 2020; 11():594556. PubMed ID: 33312177 [TBL] [Abstract][Full Text] [Related]
13. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. Iovino L; Shadman M Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458 [TBL] [Abstract][Full Text] [Related]
14. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987 [TBL] [Abstract][Full Text] [Related]
15. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Can I; Cox MJ; Siegler EL; Sakemura R; Kenderian SS Exp Hematol; 2022 Apr; 108():1-7. PubMed ID: 35150777 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapies in CLL. Park JH; Brentjens RJ Adv Exp Med Biol; 2013; 792():241-57. PubMed ID: 24014300 [TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia? Dreger P Cancer J; 2021 Jul-Aug 01; 27(4):297-305. PubMed ID: 34398556 [TBL] [Abstract][Full Text] [Related]